Abstract
Metabonomic techniques have considerable potential in the field of clinical diagnostics, typifying the application of a translational research paradigm. Care must be taken at all stages to apply appropriate methodology with accurate patient selection and profiling, and rigorous data acquisition and handling, to ensure clinical validity.
An ever-increasing number of publications in a wide range of diseases and diverse patient groups suggest a variety of potential clinical uses; prospective studies in large validation cohorts are required to bring metabonomics into routine clinical practice. In this chapter, the utility of metabonomics as a diagnostic tool will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics—a review in human disease diagnosis. Anal Chim Acta 659:23–33
Bathen TF, Jensen LR, Sitter B et al (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104:181–189
Blasco H, Corcia P, Pradat PF et al (2013) Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res 12:3746–3754
Marchesi JR, Holmes E, F K et al (2007) Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6:546–551
Kumar S, Huang J, Abbassi-Ghadi N et al (2013) Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Anal Chem 85:6121–6128
Schafer KC, Denes J, Albrecht K et al (2009) In vivo, in situ tissue analysis using rapid evaporative ionization mass spectrometry. Angew Chem Int Ed Engl 48:8240–8242
Zhang AH, Sun H, Qiu S et al (2013) NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn Reson Chem: MRC 51:549–556
Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455:1054–1056
Lindon JC, Keun HC, Ebbels TM et al (2005) The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6:691–699
Bjerrum JT, Nielsen OH, Wang YL et al (2008) Technology insight: metabonomics in gastroenterology-basic principles and potential clinical applications. Nat Clin Pract Gastroenterol Hepatol 5:332–343
Tuck MK, Chan DW, Chia D et al (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8:113–117
Ma Y, Zhang P, Yang Y et al (2012) Metabolomics in the fields of oncology: a review of recent research. Mol Biol Rep 39:7505–7511
Fan X, Bai J, Shen P (2005) Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Proc IEEE Eng Med Biol Soc 6:6081–6084
Mountford CE, Somorjai RL, Malycha P et al (2001) Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br J Surg 88:1234–1240
Lean C, Doran S, Somorjai RL et al (2004) Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat 3:551–556
Bathe OF, Shaykhutdinov R, Kopciuk K et al (2011) Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 20:140–147
OuYang D, Xu J, Huang H et al (2011) Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 165:148–154
Davis VW, Schiller DE, Eurich D et al (2013) Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol 20(Suppl 3):S415–S423
Leichtle AB, Ceglarek U, Weinert P et al (2013) Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics 9:677–687
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
Abbassi-Ghadi N, Kumar S, Huang J et al (2013) Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer 49:3625–3637
Qiu Y, Cai G, Su M et al (2009) Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 8:4844–4850
Cheng Y, Xie G, Chen T et al (2012) Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res 11:1354–1363
Bertini I, Cacciatore S, Jensen BV et al (2012) Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res 72:356–364
Shariff MI, Gomaa AI, Cox IJ et al (2011) Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res 10:1828–1836
Shariff MI, Ladep NG, Cox IJ et al (2010) Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 9:1096–1103
Wen T, Gao L, Wen Z et al (2013) Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol Biosyst 9:2370–2378
Rocha CM, Carrola J, Barros AS et al (2011) Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 10:4314–4324
Alusta P, Im I, Pearce BA et al (2010) Improving proton MR spectroscopy of brain tissue for noninvasive diagnostics. J Magn Reson Imaging: JMRI 32:818–829
Locasale JW, Melman T, Song S et al (2012) Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Mol Cell Proteomics 11:M111.014688
Nakamizo S, Sasayama T, Shinohara M et al (2013) GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neurooncol 113:65–74
Cao M, Zhao L, Chen H et al (2012) NMR-based metabolomic analysis of human bladder cancer. Anal Sci 28:451–456
Gao H, Dong B, Jia J et al (2012) Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. J Cancer Res Clin Oncol 138(5):753–761
Sreekumar A, Poisson LM, Rajendiran TM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910–914
Jentzmik F, Stephan C, Miller K et al (2010) Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58:12–18, discussion 20–11
Stabler S, Koyama T, Zhao Z et al (2011) Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One 6:e22486
Wang Y, Zhang L, Chen WL et al (2013) Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. J Proteome Res 12:4393–4401
Hilvo M, Denkert C, Lehtinen L et al (2011) Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 71:3236–3245
Sokol H, Seksik P, Rigottier-Gois L et al (2006) Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 12:106–111
Williams HR, Cox IJ, Walker DG et al (2009) Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 104:1435–1444
Stephens NS, Siffledeen J, Su X et al (2013) Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 7:e42–e48
Williams HR, Willsmore JD, Cox IJ et al (2012) Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 57:2157–2165
Schicho R, Shaykhutdinov R, Ngo J et al (2012) Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 11:3344–3357
Bjerrum JT, Nielsen OH, Hao F et al (2010) Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 9:954–962
Poordad FF (2007) Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 25(Suppl 1):3–9
Torlot FJ, McPhail MJ, Taylor-Robinson SD (2013) Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther 37:527–536
Jimenez B, Montoliu C, MacIntyre DA et al (2010) Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. J Proteome Res 9:5180–5187
Godoy MM, Lopes EP, Silva RO et al (2010) Hepatitis C virus infection diagnosis using metabonomics. J Viral Hepat 17:854–858
Holmes E, Foxall PJ, Spraul M et al (1997) 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease. J Pharm Biomed Anal 15:1647–1659
Denes J, Szabo E, Robinette SL et al (2012) Metabonomics of newborn screening dried blood spot samples: a novel approach in the screening and diagnostics of inborn errors of metabolism. Anal Chem 84:10113–10120
Oresic M, Simell S, Sysi-Aho M et al (2008) Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205:2975–2984
Wang TJ, Larson MG, Vasan RS et al (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17:448–453
Zuppi C, Messana I, Tapanainen P et al (2002) Proton nuclear magnetic resonance spectral profiles of urine from children and adolescents with type 1 diabetes. Clin Chem 48:660–662
Messana I, Forni F, Ferrari F et al (1998) Proton nuclear magnetic resonance spectral profiles of urine in type II diabetic patients. Clin Chem 44:1529–1534
Zhao X, Fritsche J, Wang J et al (2010) Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6:362–374
Buist AS (2003) Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes. Eur Respir J Suppl 39:30s–35s
McClay JL, Adkins DE, Isern NG et al (2010) (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res 9:3083–3090
Jung J, Kim SH, Lee HS et al (2013) Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy 43:425–433
Motsinger-Reif AA, Zhu H, Kling MA et al (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging. Acta Neuropathol Commun 1:28
Oresic M, Hyotylainen T, Herukka SK et al (2011) Metabolome in progression to Alzheimer’s disease. Transl Psychiatry 1:e57
Rocchetti I, Taruscio D, Pierannunzio D (2012) Modeling delay to diagnosis for amyotrophic lateral sclerosis: under reporting and incidence estimates. BMC Neurol 12:160
Tang WH, Wang Z, Cho L et al (2009) Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 53:2061–2067
Shah SH, Bain JR, Muehlbauer MJ et al (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 3:207–214
Laborde C, Mourino-Alvarez L, Posada-Ayala M et al (2014) Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. Metabolomics 10(3):414–424
Zhao YY (2013) Metabolomics in chronic kidney disease. Clin Chim Acta 422:59–69
Goek ON, Doring A, Gieger C et al (2012) Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 60:197–206
Nicholson JK, Holmes E, Kinross JM et al (2012) Metabolic phenotyping in clinical and surgical environments. Nature 491:384–392
Nicholson JK, Wilson ID, Lindon JC (2011) Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12:103–111
Clayton TA, Lindon JC, Cloarec O et al (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077
Mirnezami R, Kinross JM, Vorkas PA et al (2012) Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann Surg 255:881–889
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Hicks, L.C., Ralphs, S.J.L., Williams, H.R.T. (2015). Metabonomics and Diagnostics. In: Bjerrum, J. (eds) Metabonomics. Methods in Molecular Biology, vol 1277. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2377-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2377-9_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2376-2
Online ISBN: 978-1-4939-2377-9
eBook Packages: Springer Protocols